바이러스성 결막염 치료제 시장 : 약제 클래스별, 바이러스 유형별, 유통 채널별, 지역별

The global viral conjunctivitis drugs market is estimated to be valued at US$ 322.5 million in 2023 and is expected to exhibit a CAGR of 5.1% during the forecast period (2023-2030).

Global Viral Conjunctivitis Drugs Market Share (%), By Drug Class, 2023

Viral conjunctivitis is an acute conjunctival infection that is caused by various viruses, such adenovirus, herpes simplex virus, etc. Viral conjunctivitis is responsible for the majority of infectious conjunctivitis, accounting for up to 75% of cases. Characteristics of ocular viral conjunctivitis include redness, blood vessel engorgement, ocular discharge, pain, photophobia, etc. Viral conjunctivitis that is caused by a group of adenoviruses is called epidemic keratoconjunctivitis (EKC). This family of adenoviruses contains different serotypes that can cause pharyngoconjunctival fever and nonspecific follicular conjunctivitis as well. According to the article published in the American Academy of Ophthalmology: 2021, adenoviral conjunctivitis is the most common type of eye infection in the adult population. Adenoviral conjunctivitis is highly contagious, as the virus causing the infection can survive on a countertop or a similar surface for several weeks.

Market Dynamics

Market players are engaged in various inorganic activities such as acquisitions of companies, product approval, and others, which in turn is expected to drive growth of the global viral conjunctivitis drugs market over the forecast period. For instance, on February 2020, Bausch Health Companies Inc.'s wholly owned subsidiary, Eton Pharmaceuticals, Inc., a pharmaceutical company, announced that they had acquired the U.S. rights to Eton Pharmaceuticals' EM-100, an investigational eye drop that, if approved, would be the first over-the-counter (OTC) preservative-free formulation eye drop to be used for the treatment of ocular itching associated with conjunctivitis.

Furthermore, in July 2020, Alcon, the global leader in eye care, announced that Pataday Once Daily Relief Extra Strength (olopatadine hydrochloride ophthalmic solution 0.7%), formerly prescribed as Pazeo, had been approved by the U.S. Food and Drug Administration (FDA) for sale over-the-counter (OTC) in the U.S. Pataday Once Daily Relief Extra Strength is the first and only once-daily eye allergy itch drop offering a full 24 hours of relief without a prescription. Allergies are the sixth-leading cause of chronic illness in the U.S., generating approximately US$ 2.7 billion in OTC retail sales.

Key features of the study:

• This report provides an in-depth analysis of the global viral conjunctivitis drugs market and provides market size (US$ Million) and compound annual growth rate (CAGR) for the forecast period (2023-2030), considering 2022 as the base year It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global viral conjunctivitis drugs market based on the following parameters- company highlights, products portfolio, key highlights, financial performance, and strategies.
• Key companies covered as a part of this study include AbbVie Inc., Takeda Pharmaceutical Company Limited, Bausch Health Companies Inc., Panoptes Pharma Ges.m.b.H, NovaBay Pharmaceuticals, Inc., Nicox, NanoViricides Inc., Novartis International AG, Pfizer Inc., Johnson & Johnson, GlaxoSmithKline Plc., Santen Pharmaceutical Co.Ltd., Alcon and Okogen Inc.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• Global viral conjunctivitis drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global viral conjunctivitis drugs market.

Detailed Segmentation:

• By Drug Class:
  • Antibiotics
  • Artificial tears
  • Decongestants
  • Anti-histamines
  • NSAIDS
  • Anti-Viral drugs
  • Others (Steroids, etc.)
• By Viral Type:
  • Adenovirus
  • Enterovirus
  • Others (Herpes Simplex Virus (HSV), etc.)
• By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Region:
  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East
  • Africa
• Company Profiles
  • AbbVie Inc.
  • Takeda Pharmaceutical Company Limited
  • Bausch Health Companies Inc.
  • Panoptes Pharma Ges.m.b.H
  • NovaBay Pharmaceuticals, Inc.
  • Nicox, NanoViricides Inc.
  • Novartis International AG
  • Pfizer Inc.
  • Johnson & Johnson
  • GlaxoSmithKline Plc.
  • Santen Pharmaceutical Co.Ltd.
  • Alcon
  • Okogen Inc.

Table of Contents

1. Research Objective and Assumption

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snippet, By Drug Class
  • Market Snippet, By Virus Type
  • Market Snippet, By Distribution Channel
  • Market Snippet, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Market Opportunities
• Impact Analysis
• Recent Test Launches
• Epidemiology
• Merger, Acquisition, and Collaborations
• Regulatory Scenario
• Key Developments
• PEST Analysis

4. Global Viral Conjunctivitis Drugs Market - COVID-19 Impact Analysis

• Economic Impact
• COVID-19 Epidemiology
• Impact on Supply and Demand

5. Global Viral Conjunctivitis Drugs Market, By Drug Class, 2018-2030, (US$ Mn)

• Introduction
  • Market Share Analysis, 2023 and 2030 (%)
  • Y-o-Y Growth Analysis, 2018-2030
  • Segment Trends
• Antibiotics
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
  • Segment Trends
• Artificial tears
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
  • Segment Trends
• Decongestants
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
  • Segment Trends
• Anti-histamines
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
  • Segment Trends
• NSAIDS
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
  • Segment Trends
• Anti-Viral drugs
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
  • Segment Trends
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018 -2030, (US$ Mn)
  • Segment Trends

6. Global Viral Conjunctivitis Drugs Market, By Virus Type, 2018 - 2030, (US$ Mn)

• Introduction
  • Market Share Analysis, 2023 and 2030 (%)
  • Y-o-Y Growth Analysis, 2018-2030
  • Segment Trends
• Adenovirus
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
  • Segment Trends
• Enterovirus
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
  • Segment Trends
• Others (Herpes Simplex Virus (HSV), etc.)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
  • Segment Trends

7. Global Viral Conjunctivitis Drugs Market, By Distribution Channel, 2018 - 2030, (US$ Mn)

• Introduction
  • Market Share Analysis, 2023 and 2030 (%)
  • Y-o-Y Growth Analysis, 2018-2030
  • Segment Trends
• Hospital Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
• Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
• Online Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)

8. Global Viral Conjunctivitis Drugs Market, By Region, 2018-2030, (US$ Mn)

• Introduction
  • Market Share Analysis, 2023 and 2030 (%)
  • Y-o-Y Growth Analysis, 2018-2030
  • Segment Trends
• North America
  • Introduction
  • Market Size and Forecast, Y-o-Y Growth and By Drug Class, 2018-2030, (US$ Mn)
  • Market Size and Forecast, Y-o-Y Growth and By Virus Type, 2018-2030, (US$ Mn)
  • Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2018-2030, (US$ Mn)
  • Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018-2030, (US$ Mn)
• U.S.
• Canada
• Europe
  • Introduction
  • Market Size and Forecast, Y-o-Y Growth and By Drug Class, 2018-2030, (US$ Mn)
  • Market Size and Forecast, Y-o-Y Growth and By Virus Type, 2018-2030, (US$ Mn)
  • Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2018-2030, (US$ Mn)
  • Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018-2030, (US$ Mn)
• U.K.
• Germany
• Italy
• France
• Spain
• Russia
• Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, Y-o-Y Growth and By Drug Class, 2018-2030, (US$ Mn)
  • Market Size and Forecast, Y-o-Y Growth and By Virus Type, 2018-2030, (US$ Mn)
  • Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2018-2030, (US$ Mn)
  • Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018-2030, (US$ Mn)
• China
• India
• Japan
• ASEAN
• Australia
• South Korea
• Rest of Asia Pacific
• Latin America
  • Introduction
  • Market Size and Forecast, Y-o-Y Growth and By Drug Class, 2018-2030, (US$ Mn)
  • Market Size and Forecast, Y-o-Y Growth and By Virus Type, 2018-2030, (US$ Mn)
  • Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2018-2030, (US$ Mn)
  • Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018-2030, (US$ Mn)
• Brazil
• Mexico
• Argentina
• Rest of Latin America
• Middle East
  • Introduction
  • Market Size and Forecast, Y-o-Y Growth and By Drug Class, 2018 -2030, (US$ Mn)
  • Market Size and Forecast, Y-o-Y Growth and By Virus Type, 2018-2030, (US$ Mn)
  • Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2018-2030, (US$ Mn)
  • Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018-2030, (US$ Mn)
• GCC
• Israel
• Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, Y-o-Y Growth and By Drug Class, 2018-2030, (US$ Mn)
  • Market Size and Forecast, Y-o-Y Growth and By Virus Type, 2018-2030, (US$ Mn)
  • Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2018-2030, (US$ Mn)
  • Market Size and Forecast, By Country, Y-o-Y Growth and By Country/ Region, 2018-2030, (US$ Mn)
• North Africa
• Central Africa
• South Africa

9. Competitive Landscape

• Company Profiles
  • AbbVie Inc.
• Company Overview
• Product Portfolio
• Key Highlights
• Financial Overview
• Strategies
  • Takeda Pharmaceutical Company Limited
• Company Overview
• Product Portfolio
• Key Highlights
• Financial Overview
• Strategies
  • Bausch Health Companies Inc.
• Company Overview
• Product Portfolio
• Key Highlights
• Financial Overview
• Strategies
  • Panoptes Pharma Ges.m.b.H
• Company Overview
• Product Portfolio
• Key Highlights
• Financial Overview
• Strategies
  • NovaBay Pharmaceuticals, Inc.
• Company Overview
• Product Portfolio
• Key Highlights
• Financial Overview
• Strategies
  • Nicox, NanoViricides Inc.
• Company Overview
• Product Portfolio
• Key Highlights
• Financial Overview
• Strategies
  • Novartis International AG
• Company Overview
• Product Portfolio
• Key Highlights
• Financial Overview
• Strategies
  • Pfizer Inc.
• Company Overview
• Product Portfolio
• Key Highlights
• Financial Overview
• Strategies
  • Johnson & Johnson
• Company Overview
• Product Portfolio
• Key Highlights
• Financial Overview
• Strategies
  • GlaxoSmithKline Plc.
• Company Overview
• Product Portfolio
• Key Highlights
• Financial Overview
• Strategies
  • Santen Pharmaceutical Co.Ltd.
• Company Overview
• Product Portfolio
• Key Highlights
• Financial Overview
• Strategies
  • Alcon
• Company Overview
• Product Portfolio
• Key Highlights
• Financial Overview
• Strategies
  • Okogen Inc.
• Company Overview
• Product Portfolio
• Key Highlights
• Financial Overview
• Strategies

10. Section

• References
• Research Methodology
• About us and Sales Contact